US National Institutes of Health: Targeted in Vivo Delivery of Gene Therapeutics for HIV Cure (R01 Clinical Trial Not Allowed)

This opportunity uses the R01 Research Project Grant funding mechanism.

This supports the development and evaluation of novel targeting technologies to deliver anti-HIV gene therapies to specific cells or sites in vivo. Some of the challenges to be overcome with in vivo gene therapeutic strategies are:

  • inefficient delivery to specific target cells and sites;
  • selective regulation of genetic payload expression to maximise on-target efficacy and minimise off-target effects;
  • the potential immunogenicity of delivery vectors and transgenes themselves.

Funding & Duration

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Dates

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences. Bookmark the permalink.

Comments are closed.